Ovarian clear cell cancer
MONDO:0000548An invasive malignant neoplasm that arises from the ovary and is characterized by a predominance of clear and hobnail malignant epithelial cells.
Also known as: malignant ovarian clear cell neoplasm, malignant ovarian clear cell tumor, malignant ovarian clear cell tumour, ovarian clear cell carcinoma
2892 clinical trials for this condition and its sub-types, 30 tagged with Ovarian clear cell cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Ovarian clear cell cancer
-
Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types
1 sub-type
-
Can a pill target cancers with a specific gene flaw?
Disease control Not yet recruitingThis phase II trial tests an experimental drug called TR115 in people with advanced solid tumors that have a mutation in the ARID1A gene. The study includes patients with platinum-resistant ovarian clear cell carcinoma, endometrial cancer that failed immunotherapy, and other tumo…
Phase 2 • Sponsor: Tarapeutics Science Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat gynecologic cancers
Disease control Not yet recruitingThis study tests a new drug called BRY812 in people with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The goal is to see if the drug can shrink tumors and how safe it is. About 56 participants will receive the drug, and researc…
Phase 2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New triple therapy takes on hard-to-treat ovarian cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—liposomal irinotecan, sintilimab, and anlotinib—in 36 people with recurrent or persistent ovarian clear cell carcinoma. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have alre…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for rare ovarian cancer: drug shrinks tumors after immunotherapy fails
Disease control Not yet recruitingThis study tests a drug called sacituzumab in 22 people with a rare and aggressive type of ovarian cancer (clear cell carcinoma) that has worsened after immunotherapy. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to see how man…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC